OjO Ophthalmology jobs Online. Recruit Ophthalmologists and Optometrists with OjO. Naturally Relational Ophthalmology and Optometry Recruiters. List Your Practice for Sale too with OjO.

Wills Eye Hospital Logo

This is really great news!  Here's some incredible news from one of the best Ophthalmology training and eye research centers in the U.S.; Wills Eye Hospital. Take a look.

wills eye hospital study device for the blind

WILLS EYE SPONSORS FIRST U.S. STUDY OF DEVICE FOR BLIND RETINITIS PIGMENTOSA PATIENTS

WILLS EYE HOSPITAL SPONSORS FIRST U.S. “EARLY FEASIBILITY STUDY” OF NEW IMPLANTABLE DEVICE FOR BLIND RETINITIS PIGMENTOSA PATIENTS
Wills Eye Hospital has been given Food and Drug Administration (FDA) approval to begin an early feasibility study (EFS) to implant the RETINA IMPLANT Alpha AMS sub-retinal device in patients blind due to Retinitis Pigmentosa (RP). The Alpha AMS is manufactured by Retina Implant AG, Reutlingen, Germany and has been designed to replace the non-functioning and absent photoreceptor cells in the eye lost to the RP deterioration. The surgically implanted Alpha AMS chip stimulates the remaining components of the visual system to restore limited functional vision in blind RP patients. The eye’s own natural focusing system (without the need of a camera) focuses light on a chip made of 1600 photo diodes. The RETINA IMPLANT Alpha AMS is an investigational device in the US and has CE Mark approval in Europe since 2016.

“This study represents the very earliest phase of clinically testing a potential new option for patients and families grappling with the devastating blindness caused by Retinitis Pigmentosa. We are thankful for the smooth process in working with the FDA and for the opportunity of offering this exciting technology in the form of an EFS investigational study to our blind RP patients for the first time in the U.S.” noted Julia A. Haller, MD, Wills Eye Hospital Ophthalmologist-in-Chief.

Retinitis pigmentosa is a degenerative eye disease which is the leading cause of inherited blindness in the developed world. There is no known cure for RP which affects an estimated 100,000 people in the USA and 1.5 million people worldwide. Approximately 1,500 individuals with RP each year progress to total blindness. Wills Eye Hospital is the only site in North America conducting this investigational research study and will enroll up to eight patients for implantation. If this initial study demonstrates encouraging results, a larger pivotal study will be performed to gain FDA approval.

Here's a link to the original article at Wills Eye Hospital: https://www.willseye.org/wills-eye-sponsors-first-u-s-study-of-device-for-blind-retinitis-pigmentosa-patients/

Here's a neat fact about the Wills Eye Hospital: More ophthalmologists have trained at Wills Eye than any other program in the U.S.

 Wills Eye Hospital is absolutely unique in all the world: a gift of the Quaker merchant James Wills to the City of Philadelphia in 1832.  He gave the fortune he made from his grocery business, to build a hospital for the indigent blind – and thus Wills became the nation’s first eye specialty hospital.  
 In 1839, the first physician to be trained in Ophthalmology as a specialty came to Wills, and in our 185 years of existence we have trained the most ophthalmologists of any program in the country. 
Published in Ophthalmology News